An intent-to-treat analysis of pooled data corrected for drug exposure time showed that the incidence of laboratory-confirmed influenza illness ( LCII ) was greater in placebo - ( 7 cases/101 subjects ) than CVT-E002-treated ( 1/97 ) groups ( odds ratio ( OR ) = 7.73 , P = .033 ) .
